Pacific Biosciences of California Inc. (PacBio) announced preliminary unaudited revenue for the fourth quarter of 2025 of approximately $44.6 million, representing a year-over-year increase of 14% compared to $39.2 million in the same period of 2024. Full year 2025 revenue was approximately $160.0 million, up 4% from $154.0 million in 2024. Instrument revenue for 2025 was approximately $53.8 million, down from $65.8 million in 2024. Consumable revenue rose to approximately $81.9 million in 2025, compared to $70.3 million in 2024. Service and other revenue was approximately $24.3 million in 2025, up from $17.9 million the previous year. The company reported 61 Revio system placements and 140 Vega system placements in 2025, compared to 97 Revio and 7 Vega placements in 2024. Annualized Revio pull-through per system was approximately $242,000 in 2025, similar to $240,000 in 2024. PacBio ended 2025 with approximately $279.5 million in cash, cash equivalents, and investments, compared to $389.9 million at the end of 2024. These results are preliminary and unaudited, and final audited results may differ.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacific Biosciences of California Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623596) on January 12, 2026, and is solely responsible for the information contained therein.